Gilead Sciences, Inc. (NASDAQ:GILD) Receives $115.39 Consensus Target Price from Analysts

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given a consensus rating of “Moderate Buy” by the twenty-eight research firms that are currently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $117.1667.

Several analysts recently issued reports on GILD shares. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research report on Friday, August 8th. UBS Group lifted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a report on Tuesday, August 19th. Finally, Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $113.62 on Tuesday. The company has a fifty day simple moving average of $114.01 and a 200 day simple moving average of $110.07. Gilead Sciences has a 12-month low of $81.83 and a 12-month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market cap of $140.98 billion, a P/E ratio of 22.63, a PEG ratio of 0.76 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the firm posted $2.01 EPS. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s payout ratio is currently 62.95%.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer directly owned 595,725 shares of the company’s stock, valued at $67,692,231.75. The trade was a 1.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,390,030 over the last quarter. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Valeo Financial Advisors LLC boosted its holdings in shares of Gilead Sciences by 26.9% in the 2nd quarter. Valeo Financial Advisors LLC now owns 13,278 shares of the biopharmaceutical company’s stock worth $1,472,000 after buying an additional 2,811 shares during the last quarter. NWF Advisory Services Inc. boosted its holdings in shares of Gilead Sciences by 16.0% in the 2nd quarter. NWF Advisory Services Inc. now owns 2,162 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 299 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Gilead Sciences by 3.6% in the 2nd quarter. Osaic Holdings Inc. now owns 204,115 shares of the biopharmaceutical company’s stock worth $22,650,000 after buying an additional 7,166 shares during the last quarter. Total Investment Management Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $61,000. Finally, Centaurus Financial Inc. boosted its holdings in shares of Gilead Sciences by 14.4% in the 2nd quarter. Centaurus Financial Inc. now owns 5,824 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 731 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.